A$ 0.17
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx,...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of LDX.AX is 0.10 and suggests 39% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d
